Published on 09/12/2025

Model Explainability for QA/RA Reviewers

Introduction to Real-Time Release Testing in Pharmaceutical Manufacturing

Real-time release testing (RTRT) is a pivotal aspect of modern pharmaceutical manufacturing, particularly with the advent of continuous manufacturing processes. The integration of Process Analytical Technology (PAT) has enabled real-time quality assurance, allowing manufacturers to assess critical quality attributes (CQAs) and steadfastly ensure product quality throughout the manufacturing cycle. This approach is supported by regulatory authorities such as the US FDA and European Medicines Agency (EMA), who emphasize the need for robust validation methodologies.

The key to effective RTRT lies in the validation of multivariate models that govern manufacturing decisions. Thus, understanding the framework for model explainability becomes essential for Quality Assurance (QA) and Regulatory Affairs (RA) professionals. This guide will provide step-by-step instructions for implementing model validation consistent with regulatory expectations under 21 CFR Part 11 and EU GMP Annex 15, equipping professionals with the necessary tools for inspection-readiness.

Understanding Process Analytical Technology (PAT)

Process Analytical Technology is an integrated system used for designing, analyzing, and controlling manufacturing through timely measurements of critical quality and performance attributes. PAT aligns closely with the principles of Quality by Design (QbD), which promotes the development of processes that ensure product quality from the outset. The regulatory guidance set forth in the ICH guidelines further supports this approach.

Key elements of PAT include:

• Real-Time Data Acquisition: Continuous data collection allows for immediate responses to deviations from specified parameters.
• Multivariate Analysis: Use of statistics to analyze data from multiple variables simultaneously, facilitating a comprehensive understanding of production processes.
• Enhanced Process Understanding: In-depth insights into production dynamics, enabling proactive adjustments to maintain quality.

For successful PAT implementation, it is essential to establish a solid foundation for multivariate model validation, which forms the crux of real-time release testing. This encompasses not only model development but also ongoing maintenance and justification for the chosen analysis methods.

Framework for Multivariate Model Validation

Effective multivariate model validation is predicated upon adherence to regulatory standards and best practices. The validation process can be broken down into a series of critical steps:

Step 1: Define Objectives and Scope

The initial phase of model validation entails defining its intended use within the manufacturing process. Considerations should include the attributes to be measured, their potential impact on product quality, and specific regulatory requirements. This clarity will guide the subsequent steps in developing a robust validation framework.

Step 2: Data Collection and Pre-Processing

In order to construct a reliable model, accurate and relevant data must be collected from the manufacturing process. This includes not only historical data but also real-time measurements from PAT sensors. Pre-processing steps may involve:

• Data Cleaning: Removing outliers and irrelevant information.
• Normalization: Adjusting data to a common scale to facilitate comparison.
• Feature Selection: Identifying the most relevant variables that significantly impact CQAs.

Step 3: Model Development

With the processed data in hand, the next step is model development. Techniques may include regression analysis, machine learning algorithms, or other statistical methodologies that best fit the data characteristics. This model should be capable of predicting CQAs based on input process variables. Utilize tools that allow for interpretability, ensuring that QA and RA teams can comprehend and defend model decisions.

Step 4: Qualification and Validation

Validation of the model includes several activities:

• Model Qualification: Assessing whether the model meets predetermined criteria for accuracy, precision, and robustness. This phase often includes testing with independent datasets.
• Performance Metrics: Utilizing metrics such as accuracy, sensitivity, specificity, and predictive value to quantify the model’s effectiveness.
• Uncertainty Analysis: Identifying and quantifying uncertainties associated with model outputs, which are crucial for risk management practices mandated by ICH Q9.

It is essential to document the validation process thoroughly, as this may be scrutinized during regulatory inspections.

Regulatory Compliance: 21 CFR Part 11 and EU GMP Annex 15

Given the reliance on electronic records and signatures in modern pharmaceutical manufacturing, compliance with 21 CFR Part 11 is imperative. This regulation outlines the criteria under which electronic records and signatures are considered trustworthy, reliable, and equivalent to traditional paper records. The following aspects must be ensured:

• Audit Trails: An audit trails system must be in place to track data modifications with time stamps and user identification.
• Data Integrity: All data must be protected from loss or unauthorized changes, consistent with the principles of ALCOA (Attributable, Legible, Contemporaneous, Original, and Accurate).
• User Access Controls: Appropriate restrictions should be enforced to protect sensitive data.

Moreover, adherence to EU GMP Annex 15, which addresses the validation of computer systems, should also be a primary focus. Both regulations emphasize the importance of having a structured approach to model validation and continuous monitoring.

Ongoing Model Monitoring and Maintenance

Consistency and reliability of multivariate models require continuous monitoring throughout the manufacturing lifecycle. This entails an ongoing assessment of the model’s performance in reflecting the current state of the manufacturing process. Deviation analysis should include:

• Real-Time Monitoring: Utilizing PAT technology to monitor critical quality attributes continuously.
• Revalidation Criteria: Predefined scenarios requiring revalidation, such as significant process changes or model performance degradation.
• Adequate Documentation: Maintaining clear and comprehensive records that detail model performance, including ongoing adjustments and justifications.

Additionally, regulatory requirements must be continuously evaluated to ensure compliance with any new developments or interpretations coming from bodies such as the FDA or EMA.

Conclusion

The successful implementation of real-time release testing through effective multivariate model validation not only enhances product quality but also satisfies regulatory expectations. By following the outlined steps—ranging from objective definition to ongoing monitoring—QA and RA professionals can ensure their models remain robust, interpretable, and compliant with 21 CFR Part 11, EU GMP Annex 15, and other relevant guidelines. Achieving model explainability is not merely a regulatory checkbox but a commitment to delivering high-quality pharmaceutical products with minimized risk.

Through continuous learning and adaptation of best practices, the pharmaceutical industry can leverage the capabilities of continuous manufacturing and PAT, ultimately leading to safer and more effective therapies for patients worldwide.